Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease
Roche Venture Fund joins existing major investors Epidarex Capital, Sofinnova Partners and BioGeneration VenturesSeptember 13, 2023: Glasgow, Scotland – Mironid,...